Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Amisulpride

FDA-approved product (solution, intravenous), marketed as Barhemsys.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Amisulpride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Nausea and vomiting
  • Post operative nausea and vomiting
  • Psychosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Benzamides
FDA pharmacologic class
Dopamine-2 Receptor Antagonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA41.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli42.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae35.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis66.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Amisulpride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Amisulpride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Effectiveness and Safety of Amisulpride in Chinese Patients With Schizophrenia

    NCT01795183 · start 2012-11

    Registered record
    Registry ID
    NCT01795183
    Conditions
    Schizophrenia
    Interventions
    AMISULPRIDE
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-11
    Completion
    2013-12
    Enrolment
    316

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionAMISULPRIDE
    PhasePhase 4
    Registry statusCompleted

  • Comparison of Antipsychotic Combination Treatment of Olanzapine and Amisulpride to Monotherapy

    NCT01609153 · start 2012-06

    Registered record
    Registry ID
    NCT01609153
    Conditions
    Schizophrenia; Schizoaffective Disorder
    Interventions
    Olanzapine; Amisulpride; Olanzapine and Amisulpride
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-06
    Completion
    2019-04
    Enrolment
    328

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Schizoaffective Disorder
    InterventionOlanzapine; Amisulpride; Olanzapine and Amisulpride
    PhasePhase 4
    Registry statusCompleted

  • Optimisation of Antipsychotic Drug Use in Older People

    NCT01454453 · start 2012-05

    Registered record
    Registry ID
    NCT01454453
    Conditions
    Alzheimer's Disease; Schizophrenia
    Interventions
    Patients- dose titration
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2012-05
    Completion
    2015-07
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer's Disease; Schizophrenia
    InterventionPatients- dose titration
    PhasePhase 4
    Registry statusTerminated

  • The Effects of Dopamine on Reward Processing

    NCT01253421 · start 2012-02

    Registered record
    Registry ID
    NCT01253421
    Conditions
    Major Depressive Disorder (MDD)
    Interventions
    amisulpride; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-02
    Completion
    2016-05
    Enrolment
    159

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder (MDD)
    Interventionamisulpride; placebo
    PhasePhase 1
    Registry statusCompleted

  • Amisulpride Augmentation in Clozapine-unresponsive Schizophrenia

    NCT01246232 · start 2011-09

    Registered record
    Registry ID
    NCT01246232
    Conditions
    Schizophrenia
    Interventions
    Amisulpride; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-09
    Completion
    2015-03
    Enrolment
    69

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionAmisulpride; placebo
    PhasePhase 4
    Registry statusCompleted

  • Optimization of Treatment and Management of Schizophrenia in Europe

    NCT01248195 · start 2011-05

    Registered record
    Registry ID
    NCT01248195
    Conditions
    Schizophrenia; Schizophreniform Disorder; Schizoaffective Disorder
    Interventions
    Amisulpride open label; 6-week amisulpride double blind treatment; 6-week olanzapine double blind treatment; 12-week clozapine open-label treatment; Psychosocial intervention
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-05
    Completion
    2016-04
    Enrolment
    479

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Schizophreniform Disorder; Schizoaffective Disorder
    InterventionAmisulpride open label; 6-week amisulpride double blind treatment; 6-week olanzapine double blind treatment; 12-week clozapine open-label treatment +1 more
    PhasePhase 4
    Registry statusCompleted

  • Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia

    NCT01323205 · start 2011-05

    Registered record
    Registry ID
    NCT01323205
    Conditions
    Schizophrenia
    Interventions
    JNJ-40411813; JNJ-40411813; Placebo; Antipsychotic medication
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-05
    Completion
    2012-12
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionJNJ-40411813; JNJ-40411813; Placebo; Antipsychotic medication
    PhasePhase 2
    Registry statusCompleted

  • Optimization of Treatment and Management of Schizophrenia in Europe (OPTIMISE): Substudy Site Copenhagen

    NCT01555814 · start 2011-05

    Registered record
    Registry ID
    NCT01555814
    Conditions
    Schizophrenia; Schizophreniform Disorder; Schizoaffective Disorder
    Interventions
    Amisulpride
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2011-05
    Completion
    2016-10
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Schizophreniform Disorder; Schizoaffective Disorder
    InterventionAmisulpride
    PhaseNot applicable
    Registry statusCompleted

  • Efficacy of an Early Antipsychotic Switch in Case of Poor Initial Response to the Treatment of Schizophrenia

    NCT01029769 · start 2009-12

    Registered record
    Registry ID
    NCT01029769
    Conditions
    Schizophrenia; Schizoaffective Disorder; Schizophreniform Disorder
    Interventions
    Olanzapine or amisulpride
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2009-12
    Completion
    2015-03
    Enrolment
    350

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Schizoaffective Disorder; Schizophreniform Disorder
    InterventionOlanzapine or amisulpride
    PhaseNot applicable
    Registry statusCompleted

  • Identification and Treatment Response Prediction of Antipsychotic-Related Metabolic Syndrome

    NCT00956189 · start 2009-11

    Registered record
    Registry ID
    NCT00956189
    Conditions
    Metabolic Syndrome X
    Interventions
    amisulpride; aripiprazole
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2009-11
    Completion
    2012-10
    Enrolment
    132

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetabolic Syndrome X
    Interventionamisulpride; aripiprazole
    PhaseNot applicable
    Registry statusCompleted

  • Pan European Collaboration on Antipsychotic Naive Schizophrenia (PECANS)

    NCT01154829 · start 2008-12

    Registered record
    Registry ID
    NCT01154829
    Conditions
    Schizophrenia
    Interventions
    amisulpride; aripiprazole
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2008-12
    Completion
    2016-05
    Enrolment
    136

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    Interventionamisulpride; aripiprazole
    PhaseNot applicable
    Registry statusCompleted

  • Benzamide Derivates as Treatment of Clozapine-induced Hypersalivation

    NCT00534573 · start 2008-11

    Registered record
    Registry ID
    NCT00534573
    Conditions
    Clozapine-induced Hypersalivation
    Interventions
    Amisulpride, Moclobemide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-11
    Completion
    2009-01
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionClozapine-induced Hypersalivation
    InterventionAmisulpride, Moclobemide
    PhasePhase 3
    Registry statusCompleted

  • A Randomized, Double-blind, Comparison of the Efficacy and Safety of Amisulpride Versus Low-dose Amisulpride Plus Low-dose Sulpiride in the Treatment of Schizophrenia

    NCT01615185 · start 2008-01

    Registered record
    Registry ID
    NCT01615185
    Conditions
    Schizophrenia
    Interventions
    full-dose amisulpride
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2008-01
    Completion
    2011-12
    Enrolment
    96

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    Interventionfull-dose amisulpride
    PhasePhase 4
    Registry statusTerminated

  • Characterize The Modulatory Effects Of Dopamine D2/D3 Receptor Agonist And Antagonist Drugs On Compulsive Behaviors

    NCT00471588 · start 2006-08

    Registered record
    Registry ID
    NCT00471588
    Conditions
    Obsessive-Compulsive Disorder
    Interventions
    Pramipexole, Amisulpride
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-08
    Completion
    2007-12
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObsessive-Compulsive Disorder
    InterventionPramipexole, Amisulpride
    PhasePhase 1
    Registry statusCompleted

  • Amisulpride in Schizophrenic Acute Phase Patients

    NCT00436371 · start 2005-05

    Registered record
    Registry ID
    NCT00436371
    Conditions
    Schizophrenia
    Interventions
    Amisulpride
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-05
    Completion
    Not recorded
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionAmisulpride
    PhasePhase 4
    Registry statusCompleted